Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
about
Mutant HRAS as novel target for MEK and mTOR inhibitorsLong-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma.Maximising the potential of AKT inhibitors as anti-cancer treatmentsThe Antibiotic Drug Tigecycline: A Focus on its Promising Anticancer PropertiesSuppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCKDownregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma.Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancerSimultaneous dual targeting of Par-4 and G6PD: a promising new approach in cancer therapy? Quintessence of a literature review on survival requirements of tumor cells.Targeting RAS-mutant cancers: is ERK the key?A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).Selumetinib for the treatment of non-small cell lung cancer.Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Combine and conquer: challenges for targeted therapy combinations in early phase trials.Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.Selumetinib in the treatment of non-small-cell lung cancer.NF-κB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer.Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, SelumetinibSuccessful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease.A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatmentsThe BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.Understanding and targeting resistance mechanisms in NSCLC.miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK.Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer.Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer.MEK inhibitors for the treatment of NRAS mutant melanomaRational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment
P2860
Q27853238-C8FF8450-CF83-4173-B469-A3F1DD9E21BDQ27853310-51D2A5E8-A08D-4E02-A6A9-2D6E55080CD2Q27853330-06723FC3-517E-49A8-98ED-013FCC296203Q28072254-789216A1-0822-48E5-8AA6-4880193DDC6BQ28076402-275E97FB-326D-460B-A2B9-9149E0571B52Q28833740-5694045A-6A11-4796-AE04-ADE275712A47Q30008980-133BD6A1-5438-4E16-85C7-09D8F611C0B2Q35775241-A53F7B86-9D36-437C-B207-4D00E36FD32CQ36398735-A4D3809B-82D0-48A7-9489-8472315838B4Q37203121-28E34904-EF00-4DEF-A902-282A2F0F4FFEQ37417255-84249349-9BC4-4568-A940-E75C4A5FAAC5Q38267209-CA63C265-BB25-4053-8045-F042E2E8B22FQ38382173-AB635255-0197-4AFD-A040-AD31843101B3Q38383457-977A77C6-7D0A-4307-8E90-77ED0AA74CB3Q38387061-1E5A6430-E9F4-4F0B-9B32-5205D37EB80BQ38663069-E3EDCA80-9B14-4C67-8878-1A0C56D051B9Q38682370-25A8FDE6-3AF9-48D6-8975-A0458D6DE148Q38734451-13A8EDBA-ABC9-49B2-B24A-E8BCCB7DC7DDQ38740315-EF80B3F4-CEE2-4E85-8863-975DC9E9E45EQ38836927-0BD66A34-5891-492B-AEBE-9DCF4B849F05Q39400435-1471D406-ACD0-474E-B38E-9591CF06AFEBQ39888234-FF5FA2E6-C2D4-467D-AC28-BCBA0679D002Q40989800-7B482D3E-6113-49CE-AFDB-297557DD9C87Q41697013-9469EED3-364E-478D-BF3B-41CCC0F3E881Q41777292-7B99C55E-2998-461F-8914-0A82C5B63612Q42370827-D59159C3-739D-49F3-8DD5-6C964C9FDFC1Q42382909-CCD4AC93-39D6-4BD3-82F4-E9BD350578D9Q46915997-C4E7309A-5834-417A-B486-F9E6CD4F06C8Q47103533-65C7A24F-41C6-466B-8B2B-60B5ACCBCE94Q48234356-FC71CF99-61E4-4424-8F78-942657EF3174Q54949177-3FA6501C-1437-4D44-99FA-EE66D56E0F49Q56889985-6DD60008-2AD2-4FAE-A350-9780B3D0BDAEQ58786537-9CF0EFC3-C34F-406D-BC28-D0CAE99B6189
P2860
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
@ast
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
@en
type
label
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
@ast
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
@en
prefLabel
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
@ast
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
@en
P2093
P2860
P50
P1476
Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
@en
P2093
Amita Patnaik
Anne Morosky
Anthony W Tolcher
Brianne Kaiser
Christopher R Garrett
David Olmos
David R Gandara
Eric H Rubin
Ernestina Tetteh
Jeffrey M Skolnik
P2860
P304
P356
10.1158/1078-0432.CCR-14-1901
P407
P577
2014-12-16T00:00:00Z